高危因素对英夫利西单抗治疗克罗恩病疗效的影响
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

国家自然科学基金(81770553,82070568)


Influence of high risk factors on the efficacy of infliximab in the treatment of Crohn's disease
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:探究高危因素对英夫利西单抗(infliximab,IFX)治疗克罗恩病(Crohn’s disease,CD)临床疗效的影响。方法:纳入61例接受IFX治疗的CD患者,根据年龄、广泛肠道病变、上消化道病变和肛周病变等高危因素的数目,将CD患者分为1个高危因素组(组1)、2个高危因素组(组2)及2个以上高危因素组(组3),并根据是否广泛肠道病变或合并肛周病变进一步分组,比较各组治疗后的临床应答率和黏膜愈合率,评估高危因素对IFX疗效的影响。结果:IFX治疗后第2、6周,组1临床应答率均高于组2及组3(P < 0.05),而3组第14周临床应答率及第38周黏膜愈合率差异无统计学意义。非广泛病变亚组第2周(P=0.013)及第6周(P=0.021)临床应答率均高于广泛病变组,两组第14周临床应答率及第38周黏膜愈合率差异无统计学意义。无肛周病变组第2、6、14周临床应答率及第38周黏膜愈合率较合并肛周病变组有增高趋势,但差异均无统计学意义。结论:高危因素越少的CD患者可能越早获得临床应答,但高危因素可能并不影响CD患者的最终临床应答率及肠道黏膜愈合率。

    Abstract:

    Objective:To evaluate the effect of high-risk factors on infliximab(IFX)efficacy in patients with Crohn’s disease(CD). Methods:Sixty-one patients with CD who received IFX treatment(09/2012-05/2019)were recruited. We performed a retrospective study comparing IFX efficacy in patients with one(group 1),two(group 2)and more than two high-risk factors(group 3). Patients were also subdivided according to extensive intestine lesions and perianal lesions. The rate of clinical response/mucosal healing was used as evaluation index. Results:At week 2 and week 6,group 1 achieved higher clinical response rate than group 2 and group 3(P < 0.05),while the clinical response rate at week 14 and the mucosal healing rate at week 38 among groups were not significantly different. Patients without extensive intestine lesions achieved higher clinical response rate than those with extensive intestine lesions at week 2(P=0.013)and week 6(P=0.021),while the clinical response rate at week 14 and the mucosal healing rate at week 38 were not significantly different between groups with extensive intestine lesions or not(P > 0.05). Patients with perianal lesions or not had no significant difference on the clinical response rate and mucosal healing rate after treatment(P > 0.05). Conclusion:Patients with fewer high-risk factors may achieve clinical response earlier,but high-risk factors may not affect the final clinical response and mucosal healing rate in patients with CD.

    参考文献
    相似文献
    引证文献
引用本文

王 迪,李林珍,崔秀芳,张 丽,吴莎莎,张红杰.高危因素对英夫利西单抗治疗克罗恩病疗效的影响[J].南京医科大学学报(自然科学版),2021,(7):1044-1048

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2020-11-17
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-07-25
  • 出版日期: